Credit: RedHill Biopharma
Acute respiratory distress syndrome (ARDS)-induced thrombosis (blood clotting) may occur in up to one-third of COVID-19 patients requiring ICU admission and is a contributing cause of mortality
Opaganib demonstrated reduced thrombosis in a preclinical model of ARDS
Opaganib has also been shown to inhibit SARS-CoV-2 viral replication as well as pro-inflammatory markers in relevant preclinical models
Top-line data from the U.S. Phase 2 study of orally administered opaganib in patients with severe COVID-19, evaluating safety and potential efficacy signals, is expected later this month following the last patient s last dose administered on November 26
Top-line data from a global Phase 2/3 study of opaganib in patients with severe COVID-19, currently more than 60% enrolled, is expected in Q1/2021 with potential global emergency use applications to follow
RedHill s Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model | ANP Pers Support perssupport.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perssupport.nl Daily Mail and Mail on Sunday newspapers.
Share:
According to Coherent Market Insights, the global progressive supranuclear palsy treatment market is estimated to be valued at US$ 14.38 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).
Key Trends and Analysis:
Key trends in the market include rising incidence of progressive supranuclear palsy and ongoing research and development for treatment.
Market players are actively focusing research and development for
progressive supranuclear palsy treatment for cost effective and quality treatment. For instance, in July 2018, Asceneuron, a Switzerland-based biotechnology company received orphan drug designation, for its lead drug ASN120290 from the U.S. Food and Drug Administration (FDA). ASN120290 s therapeutic potential has been demonstrated in pre-clinical studies, indicated for the treatment of rare neurodegenerative disease, progressive supranuclear palsy (PSP).
Global Progressive Supranuclear Palsy Treatment Market to Surpass US$ 20 68 Million by 2027, Says Coherent Market Insights (CMI) - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.